Posted on 17/03/2010 in Scientific Dako has received CE accreditation for two tests designed to gauge the responsiveness of stomach cancer patients to treatment.
The company's HercepTest and HER2 FISH pharmDx diagnostic testing systems are designed to allow physicians to establish which patients are likely to benefit from use of the potentially life-prolonging treatment Herceptin.
They have been granted the CE-mark on the basis of positive results from a recent international study which demonstrated their efficacy among a test group of more than 3,700 patients.
Lars Holmkvist, chief executive officer of Dako, said this approval will assist the company's efforts to combat cancer in all its forms.
He added: "Improving the quality of stains and creating more accurate cancer diagnosis will ultimately result in better patient care."
Earlier this month, the science firm published its annual financial report, revealing that it was able to achieve record revenue levels in 2009.Other news stories from 17/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
